- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01203111
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)
Efficacy and Safety of Intensive Insulin Therapy With Insulin Glulisine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
Primary Objective:
To evaluate the efficacy of an intensive insulin regimen with insulin glargine and insulin glulisine in terms of change in Hemoglobin A1c (HbA1c) level from week 12 (visit 7) to week 24 (visit 10).
Secondary Objectives:
- Percentage of patients with HbA1c < 7% at week 24.
- Percentage of patients with HbA1c < 7% and no symptomatic nocturnal hypoglycemia event at week 24.
- Fasting Plasma Glucose (FPG) and 7-point Self Monitoring of Blood Glucose (SMBG) at week 0, week 12 and week 24.
- Doses of insulin glargine and insulin glulisine: the daily dose (U) and the daily dose / kg (U/kg) will be calculated at week 24.
- Systolic and diastolic blood pressure, heart rate, weight change will be measured at week 0, week 12 and week 24.
- Number of patients suffering hypoglycemias (asymptomatic, symptomatic, nocturnal symptomatic, severe and nocturnal severe) will be evaluated during the treatment period. 7-Adverse events.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is divided in 3 periods:
- a 2-week run-in period,
- a 12-week treatment period 1
- a 12-week treatment period 2 study treatment duration per patient: 24 weeks study duration per patient: 26 weeks
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Algiers, Algeria
- Administrative Office
-
-
-
-
-
Sao Paulo, Brazil
- Administrative Office
-
-
-
-
-
Natanya, Israel
- Administrative Office
-
-
-
-
-
Beirut, Lebanon
- Administrative Office
-
-
-
-
-
Col. Coyoacan, Mexico
- Administrative Office
-
-
-
-
-
Casablanca, Morocco
- Administrative Office
-
-
-
-
-
Lima, Peru
- Administrative Office
-
-
-
-
-
Jeddah, Saudi Arabia
- Administrative Office
-
-
-
-
-
Dubaï, United Arab Emirates
- Administrative Office
-
-
-
-
-
Caracas, Venezuela
- Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
in the run-in period:
- Uncontrolled Type 2 diabetes mellitus defined as HbA1c level between 7,5% and 10% assessed over the past 6 months
- Male or female patients from 18-75 years old inclusive
- Body Mass Index (BMI) between 25 and 40 kg/m2
- Currently treated with a basal insulin (NPH, insulin zinc or insulin detemir), plus at least 1g metformin daily, and other Oral Glucose Lowering Drug (OGLD) if any for at least 3 months
- Signed Informed consent obtained prior to any study procedures
in the treatment period:
- HbA1c level between 7,5% and 10% assessed between week -2 and week 0
- Serum creatinine <= 135 µmol/L in men and <= 110 µmol/L in women
- Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) <= 3 times the upper limit of normal
- Negative pregnancy test for women of childbearing potential
Exclusion criteria:
- Type 1 diabetes mellitus
- Active proliferative diabetic retinopathy, defined as the application of photocoagulation or surgery performed within 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (confirmed by an optic fundus performed over the past 2 years)
- Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
- History of impaired hepatic function defined as Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal
- History of impaired renal function defined as serum creatinine >135 µmol/l in men and > 110 µmol/l in women
- History of drug or alcohol abuse
- Type 2 Diabetes Mellitus (T2DM) patients treated exclusively with OGLDs
- T2DM patients treated with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue)
- Previous treatment with insulin glulisine
- Concomitant treatment with thiazolidinediones, exenatide or pramlintide
- Treatment with systemic corticosteroids within 3 months prior to study entry
- Treatment with any investigational product within 2 months prior to study entry
- History of hypersensitivity to the study drugs or to drugs with a similar chemical structure
- Presence of mental condition that, in the opinion of the investigator, indicates that participation in the study is not in the best interest of the patient
- Presence of geographic or social conditions that would restrict or limit the patient participation for the duration of the study
- Pregnant or breast feeding women
- Women of childbearing potential not protected by effective contraceptive method of birth control
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intensive insulin regimen
Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: + insulin glulisine if HbA1c ≥7% at week 12 (end of treatment period 1)
|
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
Other Names:
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
Other Names:
|
Experimental: insulin regimen
Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: no change, if HbA1c <7% at week 12 (end of treatment period 1)
|
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in HbA1c level for patients with addition of glulisine at week 12
Time Frame: between week 12 and week 24 (end of treatment period)
|
between week 12 and week 24 (end of treatment period)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of patients with HbA1c level < 7%
Time Frame: at week 24 (end of treatment period)
|
at week 24 (end of treatment period)
|
Percentage of patients with HbA1c level < 7% and no symptomatic nocturnal hypoglycemia event
Time Frame: at week 24 (end of treatment period)
|
at week 24 (end of treatment period)
|
Fasting Plasma Glucose
Time Frame: at week 0, week 12 and week 24
|
at week 0, week 12 and week 24
|
7-point Self Monitoring of Blood Glucose
Time Frame: at week 0, week 12 and week 24
|
at week 0, week 12 and week 24
|
Daily dose of insulin glargine
Time Frame: at week 24 (end of treatment period)
|
at week 24 (end of treatment period)
|
Daily dose of insulin glulisine
Time Frame: at week 24 (end of treatment period)
|
at week 24 (end of treatment period)
|
Systolic / diastolic blood pressure, heart rate, weight change
Time Frame: from week 0 (baseline) to week 24 (end of treatment period)
|
from week 0 (baseline) to week 24 (end of treatment period)
|
Hypoglycemia (asymptomatic, symptomatic, nocturnal symptomatic, severe and nocturnal severe)
Time Frame: from week 0 (from baseline) to week 24 (end of treatment)
|
from week 0 (from baseline) to week 24 (end of treatment)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LANTU_R_05048
- U1111-1116-3517 (Other Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on INSULIN GLARGINE
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
-
SanofiCompleted
-
IRCCS San RaffaeleTerminatedType 2 Diabetes Mellitus | Peripheral Vascular DiseaseItaly
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
SanofiCompletedDiabetes Mellitus Type 2Germany
-
Johns Hopkins UniversityTerminatedHypoglycemia | Type 1 DiabetesUnited States
-
University of AarhusCompletedDiabetes Mellitus, Type 1Denmark
-
SanofiCompleted
-
Medical University of GrazCompletedDiabetes Mellitus, Type 2Austria
-
SanofiCompletedType 1 Diabetes MellitusUnited States, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Netherlands, Puerto Rico, Romania, Sweden